Research
Hormonal
SGLT2 inhibitors and GLP-1 receptor agonists provide significant cardiovascular and renal protective benefits independent of their blood glucose-lowering effects, making them suitable for treating heart failure and chronic kidney disease in diabetic patients.
If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors (like Jardiance or Farxiga) or GLP-1 agonists (like Ozempic or Trulicity). These drugs not only help control blood sugar but also protect your heart and kidneys, which is often more important than just lowering the number on the glucose meter.
StrongSupportsVERY_HIGH confidence
SGLT2 inhibitors and GLP-1 receptor agonists not only improve glycemic control but also offer cardiovascular and renal protective effects, making them direct therapeutic options for these conditions.
Why this rating
Supported by multiple large, landmark randomized controlled trials (EMPA-REG, DAPA-HF, LEADER, etc.).
Source
당뇨병 치료의 진화: 관해를 향해가는 혁신적 약물치료와 첨단 관리기기의 결합
Jong Han Choi et al. · Public Health Weekly Report · 2024
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →